ProCE Banner Activity

How I Manage Key Toxicities With Adjuvant CDK4/6 Inhibitors for Early Breast Cancer

Clinical Thought

Patients benefit the most from adjuvant CDK4/6 inhibitor therapy for HR-positive, HER2-negative early breast cancer when healthcare professionals quickly identify and manage toxicities. In this commentary, I share guidance on managing the most common and challenging toxicities: diarrhea with abemaciclib and neutropenia with ribociclib.

Released: December 22, 2023

Share

Faculty

Sarah Donahue

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC, in partnership with Breastcancer.org and Smart Patients Inc.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Smart Patients

ProCE Banner

Disclosure

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, Bydonis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, Dava Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios, Arvinas, AstraZeneca, Bayer, BeyondSpring, BioNTech, Blueprint Medicines, Bristol Myers Squibb/Systimmune, Circle Pharma, Cullinan, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/AMBRX, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/Systimmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi, Seattle Genetics.

Primary Author

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, AOCNP, has no relevant financial relationships to disclose.